Boule Diagnostics – Invitation to presentation of the interim report Q1 2024

Boule Diagnostics AB will publish the interim report for the period January–March 2024 at 07:30, Tuesday, May 7th, 2024. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors.

CEO Torben Nielsen and CFO Holger Lembrér will present and comment on the first quarter report. After the presentation there will be time for audience questions. The presentation will be held in English.

The interim report will be accessible at when published.

Please feel free to attend this event!

Time:             10.00 CEST, Tuesday, May 7th, 2024

Please follow this link to attend the event!

For more information, please contact:

Torben Nielsen, CEO and Group President, Boule Diagnostics AB,  

Holger Lembrér, CFO, Boule Diagnostics AB, , phone +46 (0)72-230 77 10

About Boule Diagnostics AB (publ)

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011.

Boule Diagnostics – Invitation to presentation of the first quarter 2024

  • Subscribe to our news